替罗非班对ST段抬高型急性心肌梗死患者血小板微粒的影响

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (12): 1403-1406.

替罗非班对ST段抬高型急性心肌梗死患者血小板微粒的影响

李益民¹, 黄进¹, 陆治平¹, 李翔宇¹, 何胜虎²

¹江苏省南京市胸科医院心内科,南京 210029,江苏;
²江苏省扬州市苏北人民医院心内科,扬州 225001,江苏

收稿日期:2014-06-05 修回日期:2014-07-05 发布日期:2020-07-20
通讯作者: 何胜虎,通信作者,男,硕士,主任医师,研究方向:冠心病基础及临床。Tel:13952796929 E-mail:sbhsh@medmail.com.cn
作者简介:李益民,男,硕士,医师,研究方向:冠脉基础及临床。Tel:13851653215 E-mail:remilee@163.com

Effects of tirofiban on the level of platelet microparticles(PMPs) in patients with acute ST-segment elevation myocardial infarction undergoing emergency interventional treatment

LI Yi-min¹, HUANG Jin¹, LU Zhi-ping¹, LI Xiang-yu¹, HE Sheng-hu²

¹Department of Cardiology, Nanjing Chest Hospital, Nanjing 210029, Jiangsu, China;
²Department of Cardiology, Northern Jiangsu People's Hospital, Yangzhou 225001, Jiangsu, China

Received:2014-06-05 Revised:2014-07-05 Published:2020-07-20

摘要/Abstract

摘要： 目的: 研究替罗非班对ST段抬高型急性心肌梗死患者血小板微粒的影响。方法: 选择62例行急诊介入手术的ST段抬高型急性心肌梗死患者,随机分为给药组(罪犯血管开通前,1～3 min 内静脉推注替罗非班 10 μg/kg 负荷剂量,继以 0.15 μg·kg^-1·min^-1静脉持续泵入 36 h)32例和对照组(未使用替罗非班)30例,分别于替罗非班应用前、应用后 10 min 抽取冠脉血 3 mL;应用替罗非班 24 h 和停用替罗非班 12 h 后分别抽取桡动脉血 3 mL,采用流式细胞术测定血小板微粒的数量,统计学分析其差异。结果: 替罗非班给药前两组血小板微粒水平差异无统计学意义(P>0.05);给药后 10 min 血小板微粒的水平降至最低(5.1%±2.7% vs 6.7%±3.2%,P=0.04);给药 24 h 后给药组血小板微粒水平仍低于对照组(5.2%±2.5% vs 6.9%±3.1%,P=0.03);停用 12 h 后血小板微粒两组差异无统计学意义(P>0.05)。结论: 替罗非班能迅速降低ST段抬高型急性心肌梗死患者的即刻体内的血小板微粒水平,达到迅速抑制活化血小板的目的。

关键词: ST段抬高型急性心肌梗死, 血小板微粒, 替罗非班, 经皮冠脉介入治疗

Abstract: AIM: To investigate the effect of tirofiban on the level of platelet microparticles(PMPs) in patients with acute ST-segment elevation myocardial infarction undergoing emergency interventional treatment. METHODS: 62 patients with acute ST-segment elevation myocardial infarction undergoing emergency interventional treatment were randomly divided into the tirofiban group (intravenous tirofiban 10 μg/kg bolus then 0.15 μg·kg^-1·min^-1 intravenous continuous infusion for 36 h, 32 cases) and control group (without tirofiban, 30 cases). The levels of PMPs were assessed before tirofiban infusion, at 10 min and 24 hours after tirofiban infusion, and at 12 hours after stopping tirofiban infusion by the flow cytometry. RESULTS: There was no significant difference in baseline of PMPs between tirofiban group and control group (P＞0.05). The level of PMPs was significantly lower in tirofiban group (5.1%±2.7%) compared with control group(6.7%±3.2%)(P<0.01) at 10 mins after tirofiban infusion.At 24 hours after tirofiban infusion, the level of PMPs in tirofiban group was significantly lower than that in control group(P=0.03).The level of PMPs was similar at 12 after stopping tirofiban use between the 2 groups(P>0.05). CONCLUSION: Tirofiban can effectively reduce the number of PMPs in patients with acute ST-segment elevation myocardial infarction undergoing emergency interventional treatment, achieve the purpose of the inhibition of activated platelets quickly.

Key words: ST-segment elevation acute myocardial infarction, platelet microparticles, tirofiban, percutaneous coronary intervention

中图分类号:

R543

李益民, 黄进, 陆治平, 李翔宇, 何胜虎. 替罗非班对ST段抬高型急性心肌梗死患者血小板微粒的影响[J]. 中国临床药理学与治疗学, 2014, 19(12): 1403-1406.

LI Yi-min, HUANG Jin, LU Zhi-ping, LI Xiang-yu, HE Sheng-hu. Effects of tirofiban on the level of platelet microparticles(PMPs) in patients with acute ST-segment elevation myocardial infarction undergoing emergency interventional treatment[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1403-1406.

参考文献

[1] Roersma F, Harrington RA, Moliterno DJ. Platelet glycoprotein Ⅱb / IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials[J].Lancet, 2002,359:189-198.
[2] 中华医学会心血管病学分会.急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志,2010,38(8):675-690.
[3] Razakjr OA, Tan HC, Yip WL,et al.Predictors of bleeding complications and thrombocytopenia with the use of abciximab during percutaneous coronary intervention[J]. J Interv Cardiol, 2005,18(1):33-37.
[4] 陈灏珠,何梅先,葛均波,等.实用心脏病学[M].4版.上海:上海科学技术出版社,2007:888-890.
[5] Suades R, Padró T, Vilahur G. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques[J]. Thromb Haemost,2012,108(6):1208-1219.
[6] 解畅.GPIIb/IIIa受体拮抗剂对血小板释放PMPs及VEGF、TXA2的影响[D].天津:天津医科大学,2012.
[7] Steinhubl SR, Talley JD, Braden GA, et al.Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention:results of the GOLD (AUoAssessing Uhegra) multicenter study[J].Circulation,2001, 103(21): 2572-2578.
[8] Juergens CP, White HD, Belardi JA, et al. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement[J]. Clin Ther, 2002,24(8):1332-1344.
[9] Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes[J]. N Engl J Med, 2009, 360(21):2176-2190.
[10] Choussat R, Black A, Bossi I, et al.Vascular complications and clinical outcome after coronary angioplasty with platelet Iib/IIIa receptor blockade[J]. Eur Heart J, 2000, 21(8): 662-667.